



M · T · T · I

Molecular Targeting Technologies, Inc.

Advancing Precision Pharmaceuticals

Seeking Corporate Partners

Incorporated to further develop technologies patented by the company's founders while at Centocor, Chris Pak obtained rights to Amiscan (^{99m}Tc -Glucarate), a necrosis imaging agent for cardiac and oncology indications. Amiscan completed Phase II trials in 500 patients. MTTI developed licensing agreements with two pharmaceutical firms which provided financial support for continuing product development.

In addition, we've captured and managed >\$20 million in federal and local grants with roughly 50 collaborators since 2011. By 2018 we created a portfolio of collaborative research projects, catalog products and assets, some entering clinical trials in 2021, poised for commercialization by 2023. The bulk of these assets are therapeutics and diagnostics targeting rare cancers.

In 2019, an investor group, MTT Holdings, committed funds for clinical development of ^{177}Lu -EBTATE. MTTI expects continued cash infusion from investors, some already engaged, focused on late-stage asset development of EBTATE and other assets.

Core competencies

- Radiopharmaceutical and theranostic development
- Fluorescent diagnostics development
- Asset acquisition and management
- Collaborator engagement and project coordination
- Preclinical and clinical translation
- Expert management of:
 - Business operations
 - Investor relations
 - Partnering
 - Grants
 - Research programs
 - Contracted services

Partnership Benefits

- A Established brand and cachè among peers with reputation for innovation in targeted theranostics
- B Experienced senior management supported by a world-class pool of advisors and consultants
- C Multiple proprietary asset platforms, backed by wholly owned IP and exclusive licenses, moving toward clinical trials
- D Broad, deep technology portfolio
- E Loyal, blue chip collaborator base across multiple scientific disciplines
- F Superb grant capture history

Pipeline

PRODUCT	TARGET	INDICATION	PRECLIN	PHASE I	PHASE II	PHASE III
THERAPEUTICS						
Rabies mAb	Rabies antigen	Rabies	Outlicensed to North China Pharmaceutical (NCPC)			
BPRDP056	Phosphatidylserine	Multiple cancers	MTTI/NHRI outlicensed to Taivex (Taiwan)			
EBTATE	SSTR2	Neuroendocrine tumors	Exclusive global license from NIH			
	SSTR2	Hürthle Cell Thyroid Cancer				
	SSTR2	Nasopharyngeal cancer				
EBRGD	integrin $\alpha\beta_3$	Glioblastoma Multiforme				
	integrin $\alpha\beta_3$	Non-small cell lung cancer				
ExoBlock	Phosphatidylserine	Advanced Melanoma immunotherapy				
DIAGNOSTICS						
TDURA	Cell death	Colorectal cancer				
¹⁸F-fluoroglucuric acid	Cell death	Misc. cancers, cardiac trauma				
^{99m}Tc-glucarate	Cell death	Misc. cancers, cardiac trauma				
PSVue-Eye Drops	Cell death	Ocular diseases				
CypH-11	NIR guided surgery	Ovarian cancer				

Business development contact

Chris Pak
President & CEO
cpak@mtarget.com

Tel: 484-557-0483 (mobile)

Ji Li, Ph.D.
COO/CFO
jli@mtarget.com

Tel: 610-738-7938